When compounded products are made in advance, which identification is required for the repackager?

• A. The final 6 digits of the terminal distributor of dangerous drug license number
• B. The patient’s name
• C. The date of compounding
• D. The lot number

Answer: (A)

Regulatory labeling and traceability for repackaged compounded products require a reliable identifier for the repackager when items are prepared ahead of time. This helps ensure accountability and enables authorities to trace back to who prepared and handled the product, which is especially important for substances governed by dangerous-drug regulations. In many jurisdictions, the repackager must carry an identifier tied to their authorization as a terminal distributor of dangerous drugs. Including the final six digits of that license number on the repackaged product provides a standardized, concise link to the regulatory entity without exposing full license details. Other label elements, like the date of compounding, the lot number, or the patient name, serve important roles—date for shelf life, lot number for batch tracking, patient name for individualized dispensing—but they do not serve to identify the repackager across all units in a consistent regulatory way.